SCHEMBL435447

SCHEMBL435447

CC(F)(F)C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622355 0.85
Fluoroacetate SCHEMBL19137909 0.83 HMGCR (0.36)
SCHEMBL29253076 0.81
SCHEMBL13792298 0.81
SCHEMBL19042194 0.79
Trifluoroacetamide SCHEMBL7739632 0.77
Trifluoroacetamide SCHEMBL27598858 0.77
SCHEMBL9722984 0.76 LMNA (0.33)
SCHEMBL15128371 0.76 LMNA (0.33)
SCHEMBL9957443 0.76 LMNA (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113382990-B Substituted pyrrolidinamide III 格吕伦塔尔有限公司 2024-11-19 CN claimed
EP-4373577-A1 ACTRII PROTEINS AND USES THEREOF Acceleron Pharma Inc. (US) 2024-05-29 EP claimed
EP-4358991-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION Acceleron Pharma Inc. (US) 2024-05-01 EP claimed
CN-117957014-A ActRII proteins and uses thereof 阿塞勒隆制药公司 2024-04-30 CN claimed
EP-4351723-A2 ACTRII PROTEINS AND USES THEREOF Acceleron Pharma Inc. (US) 2024-04-17 EP claimed
EP-4351626-A2 ACTRII PROTEINS AND USES THEREOF Acceleron Pharma Inc. (US) 2024-04-17 EP claimed
CN-117794562-A ActRII proteins and uses thereof 阿塞勒隆制药公司 2024-03-29 CN claimed
EP-4274600-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION Acceleron Pharma Inc. (US) 2023-11-15 EP claimed
CN-117015548-A Synthetic ursolic acid derivatives and methods of use thereof 里亚塔医药公司 2023-11-07 CN claimed
US-20230226146-A1 ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) ACCELERON PHARMA INC. 2023-07-20 US claimed
EP-3430903-B1 SAMPLE FIXATION AND STABILISATION GOLDSBOROUGH ANDREW SIMON (FR) 2020-10-21 EP claimed
EP-3661931-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-06-10 EP claimed
WO-2019027054-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-02-07 WO claimed
EP-3430903-A1 SAMPLE FIXATION AND STABILISATION Goldsborough, Andrew Simon (FR) 2019-01-23 EP claimed
EP-2961268-B1 SAMPLE FIXATION AND STABILISATION GOLDSBOROUGH ANDREW SIMON (FR) 2018-11-21 EP claimed
EP-2961268-A1 SAMPLE FIXATION AND STABILISATION Goldsborough, Andrew Simon (FR) 2016-01-06 EP claimed
US-20140295404-A1 SAMPLE FIXATION AND STABILISATION RNASSIST LTD. (GB) 2014-10-02 US claimed
WO-2014131906-A1 SAMPLE FIXATION AND STABILISATION GOLDSBOROUGH ANDREW SIMON (FR) 2014-09-04 WO claimed
EP-2102169-A1 INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS AstraZeneca AB (SE) 2009-09-23 EP claimed
WO-2008076048-A1 INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS ASTRAZENECA AB (SE) 2008-06-26 WO claimed